Pharma BD Deal Intelligence

Genentech, Inc. (F. Hoffmann-La Roche AG) / Hanmi Pharmaceutical Co. Ltd.

2016 · Licensing/Option · $910M · Terminated

Genentech (Roche Group) licensed exclusive worldwide rights (excluding South Korea) to Hanmi's pan-RAF inhibitor HM95573 (Phase 1) for $80M upfront plus up to $830M in development, regulatory, and commercialization milestones (~$910M total) plus tiered double-digit royalties. Strategic for Roche's targeted oncology program in BRAF/CRAF-driven tumors. Closed Q4 2016.

Key facts

• Announced Sep 29, 2016
• Closed Dec 01, 2016
• Deal value $910M
• Deal type Licensing/Option
• Therapeutic area Solid tumors driven by BRAF/CRAF mutations (melanoma, NSCLC, CRC)
• Indications Solid tumors driven by BRAF/CRAF mutations (melanoma, NSCLC, CRC)
• Key assets HM95573 (belvarafenib)
• Mechanism Selective pan-RAF (BRAF/CRAF) kinase inhibitor

← Browse all deals  ·  How we score deals